Amicus Therapeutics, Inc. (FOLD) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown
FOLD's revenue distribution by segment and geography
By Geography
FOLD Revenue Analysis (2013–2024)
As of February 28, 2026, Amicus Therapeutics, Inc. (FOLD) generated trailing twelve-month (TTM) revenue of $598.7 million, reflecting strong growth of +19.5% year-over-year. The most recent quarter (Q3 2025) recorded $169.1 million in revenue, up 9.3% sequentially.
Looking at the longer-term picture, FOLD's 5-year compound annual growth rate (CAGR) stands at +23.7%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $528.3 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), FOLD has underperformed the peer group in terms of revenue growth. Compare FOLD vs AGIO →
Peer Comparison
Compare FOLD's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FOLDCurrent | $599M | +19.5% | +23.7% | 4.7% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $528.3M | +32.3% | $475.4M | 90.0% | $24.9M | 4.7% |
| 2023 | $399.4M | +21.3% | $362.0M | 90.7% | $-77,211,000 | -19.3% |
| 2022 | $329.2M | +7.8% | $290.6M | 88.3% | $-212,120,000 | -64.4% |
| 2021 | $305.5M | +17.1% | $271.0M | 88.7% | $-206,434,000 | -67.6% |
| 2020 | $260.9M | +43.2% | $229.8M | 88.1% | $-246,998,000 | -94.7% |
| 2019 | $182.2M | +99.7% | $160.3M | 87.9% | $-304,037,000 | -166.8% |
| 2018 | $91.2M | +147.1% | $76.8M | 84.2% | $-328,777,000 | -360.3% |
| 2017 | $36.9M | +644.9% | $30.7M | 83.1% | $-441,985,000 | -1196.8% |
| 2016 | $5.0M | - | $4.1M | 83.2% | $-181,890,000 | -3668.6% |
| 2015 | $0 | -100.0% | $-1,833,000 | - | $-130,437,000 | - |
See FOLD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FOLD Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare FOLD vs AGIO
See how FOLD stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is FOLD's revenue growth accelerating or slowing?
FOLD revenue is accelerating at +19.5% year-over-year, exceeding the 5-year CAGR of +23.7%. TTM revenue reached $599M. Growth momentum has increased versus prior periods.
What is FOLD's long-term revenue growth rate?
Amicus Therapeutics, Inc.'s 5-year revenue CAGR of +23.7% reflects the sustained expansion pattern. Current YoY growth of +19.5% is above this long-term average.
How is FOLD's revenue distributed by segment?
FOLD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.